1. Investor Presentation March, 2015

2. Introduction Executive Team
Virginia Long- President
AMS
Mid America Dialysis
Renal Care Group
Christopher Pyrek – SVP Business Development
Renal Care Partners, Vivra Renal Care, Health Care Properties & Development.
John Ales– VP Business Development
USRC, Renal Care Partners., National Renal Group
John Johnson, – Executive Officer, Clinical Compliance
Jewish Hospital & St. Mary’s Healthcare System
Stites & Harbison
Humana Inc.
PROPRIETARY AND CONFIDENTIAL

3. The Company Capital Raise
Raise $5 Million: Debt+Equity.
Use of Proceeds:
Equity to develop denovo clinics.
Debt availability for acquisitions.
Working Capital.
Fees & Expenses.
Provides funding for growth through 2020.
PROPRIETARY AND CONFIDENTIAL

4. The Company History and Current Status
Founded January 5, 2014.
Primary Funding to Date:
$.8 Million in Common Stock Units – September 2014.
Current Status as of March 1, 2015:
3 De-novo deals executed.
1 acute care program in operation
PROPRIETARY AND CONFIDENTIAL

5. Industry Overview The ESRD Market
End Stage Renal Disease
Population: 615,899 patients in 2011; growing at 4.3%.
Total ESRD spending = $49.3. Billion in 2013.
$34.4 Billion Federal Government (Medicare).
$14.9 Billion Private Pay Sources.
Dialysis Treatment
In 2005, 70.3% of ESRD Population (341,000 patients).
USRDS 2020 Projection: 786,000 patients
92.4% Hemodialysis/7.6% Peritoneal Dialysis.
6o%+ of patients are served by two major providers (FMS and DVA).
PROPRIETARY AND CONFIDENTIAL

6. Industry Overview The Dialysis Population
2011: 615,899 Dialysis Patients
2020: USRDS Projection = 786,000 Patients
Incident & Prevalent Dialysis Patient Counts/Transplant Event Counts
PROPRIETARY AND CONFIDENTIAL

7. Industry Overview Growth Opportunity
ESRD/Dialysis Population Growth necessitates clinical expansion.
Dialysis population growth of 18,000-20,000 patients/year.
new clinics/year.
Major public players prefer buy versus build.
PROPRIETARY AND CONFIDENTIAL

8. The Company New Development Opportunities
Clinical Cluster Expansion
Florida
Virginia
Georgia
New Cluster Markets
Michigan
New Clinical Development
Home Program Growth
Acute Care Program Growth
Virginia
Florida
Home
Care
Acute
Care
New
Clusters/
Clinics
Georgia
PROPRIETARY AND CONFIDENTIAL

9. The Company Growth Strategy
Multiple opportunities for new clinical development.
Growing patient population.
Target certain growth and services areas:
Expiration of agreements.
Dissatisfaction with big chains.
Growing patient base.
Ownership opportunity.
Trend toward nephrology groups.
Facility Clusters in Geographic Regions.
Maximize management efficiency.
Create significant local market share for physician awareness.
Obtain provider contracts.
Create greater value.
PROPRIETARY AND CONFIDENTIAL

10. The Company Growth Strategy-Home
Home Growth – Primary Focus
- Developing market though Physician Partnerships via Joint Ventures.
- NCG ownership: 51% or more of the center.
- Increased revenue vs lower costs.
- Less initial investment
- CKD clinics, training centers
- Pathway to larger centers
PROPRIETARY AND CONFIDENTIAL

11. The Company Growth Strategy- Chronic
DeNovo Growth – Primary Focus
- Physician Partnerships via Joint Ventures.
- NCG ownership: 51% or more of the clinic.
- Facility Clusters.
PROPRIETARY AND CONFIDENTIAL

12. The Company Growth Strategy
Acquisition Based Growth – Secondary Focus
- Single or multiple clinic acquisitions in areas with strong potential for future de novo development.
- Structure: Prefer Cash/Stock combination.
- EBITDA multiples 4x-6x.
PROPRIETARY AND CONFIDENTIAL

13. The Company Growth Strategy
– Ancillary Focus
- Physician Practice acquisition and development.
- Vascular Access Centers
PROPRIETARY AND CONFIDENTIAL

14. The Company Revenue Model Assumptions
Revenue Per Patient:
$270/Treatment.
3 Treatments/Week.
12 Treatments/Month.
144 Treatments/Year.
$39,000/Patient/Year.
Medicare 85%
Private 5-10%
PROPRIETARY AND CONFIDENTIAL

15. PROPRIETARY AND CONFIDENTIAL
The Company Development Status- Currently signed
Clinic
# Stations
Patient
Capacity
Opening Date
Chantilly, VA _ UL
Q2 2015
Bethlehem, GA 4
24+
Eufala, AL
24 +
Q3 2015
Eufala,AL
Inpatient
Q1 2015
PROPRIETARY AND CONFIDENTIAL

16. PROPRIETARY AND CONFIDENTIAL

17. The Company Business Development Pipeline
PROPRIETARY AND CONFIDENTIAL

18. Conclusion Liquidity Goals, Alternatives and Timing
Objectives
Alternatives
Acquisition
Merger
Public Offering
Timing
PROPRIETARY AND CONFIDENTIAL

19. Conclusion Acquisition Multiples and Criteria
Strategic Acquisition Multiples
- 8x - 12x Clinical Contribution Margin (Clinical EBITDA before Corporate Overhead).
Valuation Considerations
Scale: # Patients / # Clinics.
Strategic Fit: Geography, Clustering, Payors.
Payor Mix.
PROPRIETARY AND CONFIDENTIAL

20. Conclusion Significant Market Transactions
Third Quarter 2013
USRC Acquires Innovative Dialysis
Third Quarter 2011
Innovative Dialysis Acquires Renal Care Partners
Fresenius Acquires Liberty Dialysis
Fourth Quarter 2010
Liberty Acquires Renal Advantage.
Fourth Quarter 2008
Renal Advantage Acquires National Renal Alliance
Opportunities Exist :
Only one other new company formation to fill the gap
PROPRIETARY AND CONFIDENTIAL